Professor of Medicine, Case West Res University
Hematology
Dr. Jaroslaw P. Maciejewski, MD
|
|
Give Review
Dr. Jaroslaw P. Maciejewski works in the field of Hematology. He has 5 awards "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Northern Ohio Live" and "Elected Member". Jaroslaw Maciejewski is also published. He has 100 publications published. The lastest publication: "Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.' Doctor Jaroslaw P. Maciejewski, MD accepts all Medicare patients.
Publications
- Angioimmunoblastic T-cell Lymphomas With the RHOA p.Gly17Val Mutation Have Classic Clinical and Pathologic Features.
- Outcomes of patients with Myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
- Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic Leukemia with low risk cytogenetic features or no metaphases.
- Genomic patterns associated with hypoplastic compared to hyperplastic Myelodysplastic syndromes.
- Comparing the prognostic value of risk stratifying models for patients with lower-risk Myelodysplastic syndromes: Is one model better?
- Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
- Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in Myeloid neoplasms.
- TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) Myelodysplastic syndromes.
- Genetic and molecular characterization of myelodysplastic syndromes and related Myeloid neoplasms.
- High rate of both hematopoietic and solid tumors associated with large granular lymphocyte Leukemia.
- Impact of vancomycin-resistant enterococcal bacteremia on outcome during Acute myeloid leukemia induction therapy.
- The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.
- Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.
- Synergistic Effect of Major Histocompatibility Complex Class I-Related Chain A and Human Leukocyte Antigen-DPB1 Mismatches in Association with Acute Graft-versus-Host ...
- Myeloid Malignancies with Chromosome 5q Deletions Acquire a Dependency on an Intrachromosomal NF-κB Gene Network.
- Genetic alterations of the cohesin complex genes in Myeloid malignancies.
- A phase II multicenter rabbit anti-thymocyte globulin trial in patients with Myelodysplastic syndromes identifying a novel model for response prediction.
- Concurrent juvenile myelomonocytic Leukemia and T-lymphoblastic lymphoma with a shared missense mutation in NRAS.
- Alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition.
- PRPF8 defects cause missplicing in Myeloid malignancies.
- Molecular pathogenesis of Myelodysplastic syndromes.
- Recurrent genetic defects on chromosome 7q in Myeloid neoplasms.
- Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in Myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.
- Deep sequencing of the T cell receptor repertoire in CD8+ T-large granular lymphocyte Leukemia identifies signature landscapes.
- Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-related AML.
- Epidemiology and risk factors for infections in Myelodysplastic syndromes.
- Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in Myeloid malignancies.
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.
- STAT3-mutations indicate the presence of subclinical T cell clones in a subset of aplastic Anemia and myelodysplastic syndrome patients.
- Somatic SETBP1 mutations in Myeloid malignancies.
- Patterns of missplicing due to somatic U2AF1 mutations in Myeloid neoplasms.
- Outcomes in obese and overweight Acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.
- Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome.
- Response to lenalidomide in Myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
- Naive T-cells in Myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.
- Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in Myeloid malignancies.
- The need for additional genetic markers for Myelodysplastic syndrome stratification: what does the future hold for prognostication?
- Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of Myeloproliferative neoplasms.
- Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in Myelodysplastic syndrome with chromosome 5q deletion.
- Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic Leukemia but largely absent in juvenile myelomonocytic leu...
- Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk Myelodysplastic syndromes.
- SF3B1 haploinsufficiency leads to formation of ring sideroblasts in Myelodysplastic syndromes.
- Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis.
- A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap Myelodysplastic/myeloprolif...
- Update on developments in the diagnosis and prognostic evaluation of patients with Myelodysplastic syndromes (MDS): Consensus statements and report from an expert work...
- Molecular lesions in childhood and adult Acute megakaryoblastic leukaemia.
- Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte Leukemia.
- Mutational spectrum analysis of chronic myelomonocytic Leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A.
- An anti-apoptotic Bcl-2 family expression index predicts the response of chronic lymphocytic Leukemia to ABT-737.
- HDAC inhibitors potentiate the apoptotic effect of enzastaurin in Lymphoma cells.
- Updates in Cytogenetics and Molecular Markers in MDS.
- Loss of expression of neutrophil proteinase-3: a contributory factor in thrombotic risk in paroxysmal nocturnal hemoglobinuria.
- SNP array-based karyotyping: differences and similarities between aplastic Anemia and hypocellular myelodysplastic syndromes.
- Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related Myeloid malignancies.
- PATHOGENESIS AND CONSEQUENCES OF UNIPARENTAL DISOMY IN CANCER.
- Perceptions of Disease State, Treatment Outcomes, and Prognosis Among Patients with Myelodysplastic Syndromes: Results From an Internet-Based Survey.
- A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary Acute myeloid leukemia.
- Optimization of therapy for severe aplastic Anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on sev...
- CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous Leukemia.
- Clonal evolution in aplastic Anemia.
- Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk Myelodysplastic syndromes.
- Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic v...
- Impact of weekend admissions on quality of care and outcomes in patients with Acute myeloid leukemia.
- T/NK large granular lymphocyte Leukemia and coexisting monoclonal B-cell lymphocytosis-like proliferations. An unrecognized and frequent association.
- Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus.
- Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk Myelodysplastic syndromes.
- Copy neutral loss of heterozygosity: a novel chromosomal lesion in Myeloid malignancies.
- Characterization of chromosome arm 20q abnormalities in Myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
- Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic Leukemia.
- Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in Myeloid malignancies.
- New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in Acute myeloid leukemia.
- Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced Myeloid malignancies.
- Loss of heterozygosity 4q24 and TET2 mutations associated with Myelodysplastic/myeloproliferative neoplasms.
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
- Clonotype analysis of cytomegalovirus-specific cytotoxic T lymphocytes.
- Diagnosis and therapy of neutropenia in large granular lymphocyte Leukemia.
- Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk Myelodysplastic syndromes.
- 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl,...
- Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
- Characteristics of US patients with Myelodysplastic syndromes: results of six cross-sectional physician surveys.
- Whole genome scanning as a cytogenetic tool in hematologic malignancies.
- Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in Chronic myeloproliferative disorders with JAK2 V617F.
- Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL Leukemia.
- Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
- Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
- Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.
- Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory Anemia with ringed sideroblasts.
- Molecular analysis of alloreactive CTL post-hemopoietic stem cell transplantation.
- CD4+CD25high Foxp3+ regulatory T cells in Myelodysplastic syndrome (MDS).
- A Decision analysis to determine the appropriate treatment for low-risk Myelodysplastic syndromes.
- Bone marrow phospho-STAT5 expression in non-CML Chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
- SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD.
- Pathophysiology defined by altered signal transduction pathways: the role of JAK-STAT and PI3K signaling in leukemic large granular lymphocytes.
- Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic Anemia and myelodysplastic syndrome.
- Refractory Anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
- Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis.
- Identification of the JAK2 V617F mutation in Chronic myeloproliferative disorders using FRET probes and melting curve analysis.
- Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles.
- Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte Leukemia.
Schools
Humboldt University
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Northern Ohio Live
- Elected Member
Education
-
National Institutes of Health Clinical Center -
University of Nevada, Reno -
Humboldt University of Berlin- Charite Faculty of Medicine
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1831299908 | |
| NPPES Provider LastName | MACIEJEWSKI | |
| NPPES Provider FirstName | JAROSLAW | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 293.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1831299908 |
| Last Name Of The Provider | MACIEJEWSKI |
| First Name Of The Provider | JAROSLAW |
| View All |
Similar Doctors
|
|
Dr. Gil S. Peleg, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith R. McCrae, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohammad Mobayed, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joseph Gibbons, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lalitha V. Nayak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aaron T. Gerds, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin A. Gartrell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roy L. Silverstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul F. Hergenroeder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hollis W. Walker Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bo Zhao, MD |